Compare HYLN & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | CADL |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.2M | 339.8M |
| IPO Year | N/A | 2021 |
| Metric | HYLN | CADL |
|---|---|---|
| Price | $1.85 | $5.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $5.00 | ★ $19.43 |
| AVG Volume (30 Days) | 936.6K | ★ 1.0M |
| Earning Date | 11-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,272,000.00 | N/A |
| Revenue This Year | $204.64 | N/A |
| Revenue Next Year | $253.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 124.55 | N/A |
| 52 Week Low | $1.11 | $4.25 |
| 52 Week High | $2.79 | $13.68 |
| Indicator | HYLN | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 53.98 |
| Support Level | $1.76 | $5.48 |
| Resistance Level | $2.04 | $5.98 |
| Average True Range (ATR) | 0.10 | 0.42 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 32.67 | 48.06 |
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.